Cellular systems – no specific molecular target identified

The classification "Cellular systems – no specific molecular target identified" is a designation used in pharmacological databases to describe therapeutic agents that produce a biological effect without a known specific molecular interactor (Gaulton et al., 2012). This category is frequently associated with phenotypic drug discovery, an approach that identifies compounds based on their ability to alter a disease-relevant phenotype in cells or tissues (Moffat et al., 2017). Historically, many successful drugs, including several general anesthetics and anti-epileptics, were discovered and utilized for years before their precise molecular targets were elucidated (Swinney & Anthony, 2011). For biotech analysts, this label signifies a lack of mechanistic clarity, which can present significant challenges during the regulatory approval process and in the assessment of safety profiles. Without a defined target, it is difficult to predict off-target toxicities or to develop precise biomarkers for patient stratification (Ziegler et al., 2013). Consequently, compounds in this category often undergo intensive "target deconvolution" using techniques like chemical proteomics to identify the underlying molecular drivers. Understanding the molecular basis of these agents is essential for transitioning from a phenotypic hit to a well-characterized clinical candidate.

Other names

Phenotypic targetUnknown molecular targetNon-specific cellular targetSystemic targetUnassigned target

The mechanism of action is not defined at the molecular level; biological activity is characterized by observable changes in cellular or systemic phenotypes (Moffat et al., 2017).